empagliflozin + pioglitazone (Boehringer Ingelheim)

**Empagliflozin + pioglitazone** is a fixed-dose combination of two oral antidiabetic drugs used in the management of type 2 diabetes mellitus. **Empagliflozin** is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose levels by blocking renal glucose reabsorption, resulting in increased urinary glucose excretion. **Pioglitazone** is a thiazolidinedione and a selective agonist for peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity in peripheral tissues and decreasing hepatic gluconeogenesis. Their combination targets complementary mechanisms, with empagliflozin acting via the kidneys and pioglitazone acting on insulin sensitivity, providing additive benefits for glycemic control, weight reduction, and blood pressure lowering, with a low risk of hypoglycemia. The combination is indicated as an adjunct to diet and exercise in adults with type 2 diabetes, especially when monotherapy is insufficient[1][5][8].

Brand names

Piemonte

Other names

empagliflozin + pioglitazoneBI 10773 + pioglitazone